All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner

Zsolt Faluhelyi, Imre Rodler, Andras Csejtey, Stephen K. Tyring, I. Ember, Istvan Arany

Research output: Article

16 Citations (Scopus)

Abstract

Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10-5-10-4 M) but not low-dose (10-7-10 -6 M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.

Original languageEnglish
Pages (from-to)807-809
Number of pages3
JournalAnticancer Research
Volume24
Issue number2 B
Publication statusPublished - márc. 2004

Fingerprint

Human papillomavirus 16
Tretinoin
Transcription Factor AP-1
Growth
Uterine Cervical Dysplasia
Oligonucleotides
Squamous Cell Carcinoma
Carcinoma
Genes
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner. / Faluhelyi, Zsolt; Rodler, Imre; Csejtey, Andras; Tyring, Stephen K.; Ember, I.; Arany, Istvan.

In: Anticancer Research, Vol. 24, No. 2 B, 03.2004, p. 807-809.

Research output: Article

Faluhelyi, Z, Rodler, I, Csejtey, A, Tyring, SK, Ember, I & Arany, I 2004, 'All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner', Anticancer Research, vol. 24, no. 2 B, pp. 807-809.
Faluhelyi, Zsolt ; Rodler, Imre ; Csejtey, Andras ; Tyring, Stephen K. ; Ember, I. ; Arany, Istvan. / All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner. In: Anticancer Research. 2004 ; Vol. 24, No. 2 B. pp. 807-809.
@article{64d38cc9bbf84dd589d9e348337a4574,
title = "All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner",
abstract = "Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10-5-10-4 M) but not low-dose (10-7-10 -6 M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.",
keywords = "E7, HPV16, Retinoids, Transcription",
author = "Zsolt Faluhelyi and Imre Rodler and Andras Csejtey and Tyring, {Stephen K.} and I. Ember and Istvan Arany",
year = "2004",
month = "3",
language = "English",
volume = "24",
pages = "807--809",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - All-trans Retinoic Acid (ATRA) Suppresses Transcription of Human Papillomavirus Type 16 (HPV16) in a Dose-dependent Manner

AU - Faluhelyi, Zsolt

AU - Rodler, Imre

AU - Csejtey, Andras

AU - Tyring, Stephen K.

AU - Ember, I.

AU - Arany, Istvan

PY - 2004/3

Y1 - 2004/3

N2 - Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10-5-10-4 M) but not low-dose (10-7-10 -6 M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.

AB - Earlier we found that SiHa cervical squamous carcinoma cells that harbor HPV type 16 respond to ATRA treatment in a dose-dependent manner: high-dose (10-5-10-4 M) but not low-dose (10-7-10 -6 M) ATRA induced growth arrest. Growth of HPV-infected cells is highly dependent on the expression of the viral E6/E7 proteins. Thus, targeting expression of the viral E6/E7 genes might influence growth properties of HPV-infected cells. Here, we demonstrated that high-dose ATRA inhibited expression of HPV16 E7 through suppression of the HPV16 promoter (p97) activity. Gelshift assay (EMSA) revealed that binding of the AP-1 transcription factor to an oligonucleotide originated from the HPV type 16 promoter was diminished after high-dose, but not low-dose ATRA treatment. This suggests that high-dose ATRA suppresses HPV 16 promoter activity, at least in part, via a decreased AP-1 binding. Our data might be useful in treatment of cervical dysplasias and/or carcinomas.

KW - E7

KW - HPV16

KW - Retinoids

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=2442528846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442528846&partnerID=8YFLogxK

M3 - Article

C2 - 15161031

AN - SCOPUS:2442528846

VL - 24

SP - 807

EP - 809

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -